Published online Nov 27, 2023. doi: 10.4240/wjgs.v15.i11.2423
Peer-review started: August 7, 2023
First decision: August 24, 2023
Revised: September 18, 2023
Accepted: October 11, 2023
Article in press: October 11, 2023
Published online: November 27, 2023
Polycystic ovary syndrome (PCOS) is a common endocrine disease in young women, with a prevalence rate of 5%-18%. PCOS is closely related to obesity, and an increase in obesity will enhance the severity and expression of the PCOS phenotype.
The efficacy of laparoscopic sleeve gastrectomy (LSG) for obesity with PCOS are still unclear.
The purpose of the study was to investigate the effect of LSG on related variables in obese patients with PCOS.
The clinical data of 32 patients who were diagnosed with obesity complicated with polycystic ovary syndrome and underwent laparoscopic sleeve gastrectomy from January 2013 to December 2020 were reviewed. The changes in anthropometric indices, insulin, testosterone, estradiol, follicle stimulating hormone (FSH), luteinizing hormone (LH), menstrual cycle and LH/FSH ratio before and 1 mo, 3 mo, 6 mo and 12 mo after the operation were statistically analyzed.
The patient's body mass and BMI were basically stable at 1 year after the operation. During the postoperative period, the average level of estradiol increased; the average serum testosterone and the insulin level decreased significantly after the operation. On the other hand, after surgical treatment, it was found that the average ratio was less than 1, indicating that the average FSH level after bariatric surgery was higher than that of LH.
Laparoscopic sleeve gastrectomy can improve hyperandrogenaemia and irregular menstruation in obese patients with polycystic ovary syndrome, significantly reduce weight loss and improve a series of complications related to polycystic ovary syndrome.
The impact of laparoscopic sleeve gastrectomy on obese patients with polycystic ovary syndrome's physical, hormonal and reproductive indicators.